Keefe Bruyette analyst Paul Johnson lowered the firm’s price target on Crescent Capital BDC (CCAP) to $15.50 from $17 and keeps an Outperform rating on the shares. The risks are more than discounted into the stock price at this point, although credit issues have not fully inflected, the analyst tells investors in a research note.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CCAP:
- Crescent Capital BDC price target lowered to $14 from $15 at Wells Fargo
- Crescent Capital BDC Reports Q3 2025 Earnings
- Crescent Capital BDC, Inc. Earnings Call Insights
- Crescent Capital BDC price target lowered to $15.50 from $16.50 at Clear Street
- Crescent Capital BDC reports Q3 EPS 46c, consensus 46c